On December 15, 2025, Cellectis, a clinical-stage biotechnology company traded on Euronext Growth with the symbol ALCLS and NASDAQ with the symbol CLLS, shared updates regarding the Arbitral Tribunal's decision on arbitration proceedings against Les Laboratoires Servier and Institut de Recherches Internationales Servier IRIS SARL. This pertains to the License, Development, and Commercialization Agreement signed between Servier and Cellectis on March 6, 2019, as amended. The Tribunal's ruling marks a significant development in the dispute resolution.